Last Updated : October 4, 2024
Details
Generic Name:
lazertinib and amivantamab
Project Status:
Pending
Therapeutic Area:
Locally advanced or metastatic non-small cell lung cancer (NSCLC)
Manufacturer:
Janssen Inc.
Call for patient/clinician input open:
Brand Name:
Lazcluze and Rybrevant
Project Line:
Reimbursement Review
Project Number:
PC0392-000
Call for patient/clinician input closed:
Tumour Type:
Lung
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Lazcluze (lazertinib) tablets in combination with Rybrevant (amivantamab) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Lazcluze (lazertinib) tablets in combination with Rybrevant (amivantamab) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : October 4, 2024